Nuvectis Pharma initiates NXP900 Phase 1b program, reports successful Phase 1a results.

• Nuvectis Pharma initiates NXP900 Phase 1b program in advanced cancers • Single-agent study underway for preliminary clinical efficacy evidence • Combination portion of the program expected by year-end • NXP900 Phase 1a dose escalation study completed with robust pharmacodynamic responses • NXP900 clinical drug-drug interaction study in healthy volunteers completed • Poster presentations at AACR-NCI-EORTC International Conference highlight NXP900's clinical profile